GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Khiron Life Sciences Corp (OTCPK:KHRNF) » Definitions » Debt-to-Revenue

Khiron Life Sciences (Khiron Life Sciences) Debt-to-Revenue : 0.19 (As of Sep. 2022)


View and export this data going back to 2018. Start your Free Trial

What is Khiron Life Sciences Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Khiron Life Sciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2022 was $0.92 Mil. Khiron Life Sciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2022 was $1.00 Mil. Khiron Life Sciences's annualized Revenue for the quarter that ended in Sep. 2022 was $10.15 Mil. Khiron Life Sciences's annualized Debt-to-Revenue for the quarter that ended in Sep. 2022 was 0.19.


Khiron Life Sciences Debt-to-Revenue Historical Data

The historical data trend for Khiron Life Sciences's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Khiron Life Sciences Debt-to-Revenue Chart

Khiron Life Sciences Annual Data
Trend May12 May13 May14 May15 May16 May17 Dec18 Dec19 Dec20 Dec21
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only N/A 2.81 0.37 0.35 0.17

Khiron Life Sciences Quarterly Data
Nov17 Feb18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.14 0.15 0.15 0.13 0.19

Competitive Comparison of Khiron Life Sciences's Debt-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Khiron Life Sciences's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Khiron Life Sciences's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Khiron Life Sciences's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Khiron Life Sciences's Debt-to-Revenue falls into.



Khiron Life Sciences Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Khiron Life Sciences's Debt-to-Revenue for the fiscal year that ended in Dec. 2021 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(1.189 + 0.551) / 9.996
=0.17

Khiron Life Sciences's annualized Debt-to-Revenue for the quarter that ended in Sep. 2022 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.919 + 1.003) / 10.152
=0.19

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Sep. 2022) Revenue data.


Khiron Life Sciences Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Khiron Life Sciences's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Khiron Life Sciences (Khiron Life Sciences) Business Description

Traded in Other Exchanges
N/A
Address
2300 - 500 Burrard Street, Vancouver, BC, CAN, V6C 2B5
Khiron Life Sciences Corp is a vertically integrated medical company with core operations in Latin America and Europe, The company's platform leverages medical health clinics and proprietary telemedicine platforms, Khiron combines a patient-oriented approach, physician education programs, scientific, product innovation, and cannabis operations expertise to drive prescriptions and brand loyalty with patients worldwide. The company has a presence in Mexico, Peru, Germany, the United Kingdom, and Brazil.